Outlook Therapeutics prices private placement warrants for 16,129,033 shares at $0.31

• Outlook Therapeutics entered a securities purchase agreement on April 22, 2026 for a registered direct offering of 16,129,033 common shares priced at USD 0.31 per share-warrant unit.
• Concurrent private placement covers common warrants for 16,129,033 shares with an exercise price of USD 0.31.
• Warrants become exercisable after stockholder approval for warrant shares issuance and an authorized share increase.
• Company plans to hold a stockholder meeting within 90 days of closing to seek the required approvals.
• Common warrants, warrant shares, placement agent warrants, and related shares were sold without registration under Securities Act exemptions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-047741), on April 23, 2026, and is solely responsible for the information contained therein.